Andere Sprachen Satellos Bioscience Inc.

Aktien

A3CSSM

CA80401L3083

MSCL

Verzögert Toronto S.E. Andere Börsenplätze 17:36:22 06.05.2024			% 5 Tage	% 1. Jan.
0,405 ^CAD	+1,25 %		-10,00 %	-5,81 %

27.03.	Satellos Bioscience Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
27.03.	Satellos Bioscience gibt die Ergebnisse für das Geschäftsjahr 2023 bekannt	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Satellos to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	08.04.
Satellos Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.03.
Satellos Bioscience: Q4 Earnings Snapshot	27.03.
Satellos Bioscience Announces FY 2023 Results	27.03.
Satellos Bioscience Announces 2023 Year End Financial Results and Operational Highlights	27.03.
Satellos to Present at Upcoming Virtual Investor Conferences in March and April	14.03.
Satellos to Participate in the Leerink Partners Global Biopharma Conference 2024	05.03.
Satellos Presented "Positive" Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference	04.03.
Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference	04.03.
Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference	04.03.
Satellos Recognized as a Top 50 TSX Venture Exchange Company	21.02.
Satellos Announces Upcoming Presentations at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference	20.02.
Satellos Bioscience Inc. Brief: Says Will commence trading on the Toronto Stock Exchange as of the opening of trading tomorrow	14.02.
Satellos to Commence Trading on the Toronto Stock Exchange	14.02.
Satellos Announces Promising Preliminary Data in Facioscapulohumeral Muscular Dystrophy	13.02.
Satellos Bioscience Inc. Announces Promising Preliminary Data in Facioscapulohumeral Muscular Dystrophy	13.02.
Satellos Announces Management Team Update	24.01.
Satellos Bioscience Inc. Brief: Shares Jumped 13.4% on Monday; Co Recently Received Conditional Approval to Graduate to the Toronto Stock Exchange	23.01.
Satellos Bioscience Inc. Brief: Announced Earlier Tuesday Management Team Update; Alan K. Jacobs, Chief Medical Officer Has Left to Pursue Other Opportunities; Jordan Dubow Engaged As Chief Medical Advisor	23.01.
Satellos Bioscience Inc. Announces Executive Changes	23.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Satellos Bioscience Inc.

Aktien

A3CSSM

CA80401L3083

MSCL

Andere Sprachen

Filter